Thrombolex recently announced the publication of RESCUE-II study results in JACC: Advances.
The RESCUE-II study was a single-centre, prospective study evaluating the safety and feasibility of on-the-table (OTT) pharmacomechanical lysis (PML) without postprocedural infusion when treating patients with acute intermediate-risk pulmonary embolism (PE). Nine patients were enrolled and successfully treated with low dose r-tPA (4mg per pulmonary artery) using the Bashir endovascular catheter (BEC).
Thrombolex reports that, at 48 hours, the mean right ventricle to left ventricle (RV/LV) ratio decreased by 22.3%, and pulmonary artery obstruction, as measured by the Refined Modified Miller Index, was reduced by 29.2%. There were no major bleeding events, no deaths or serious adverse events through 30-day follow-up.
Thrombolex advises that an independent data safety monitoring board adjudicated all clinical events for the RESCUE-II study, while imaging data were assessed by an independent Core laboratory.
